By Bob Paterson For someone diagnosed with a meningioma after years of contraceptive injections, the Depo-Provera lawsuit raises a deeply personal question: should patients have received clearer warnings about the potential risk? These are genuine filed cases. Patients allege that injectable medroxyprogesterone acetate caused their tumors and that manufacturers failed to provide adequate warnings. The manufacturers dispute the allegations. Federal cases are coordinated in a Florida court, and a settlement program now covers a substantial portion of the litigation.
The distinction matters for anyone following the news. A filed lawsuit establishes that claims exist; it does not establish that every allegation is proven. Likewise, a settlement does not mean every former Depo-Provera user qualifies for compensation.
Where Was the Depo-Provera Lawsuit Filed?
On February 7, 2025, the Judicial Panel on Multidistrict Litigation centralized federal cases in the Northern District of Florida. The proceeding is In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, under Judge M. Casey Rodgers. Its master case number is 3:25-md-3140.
The court identifies the central disputes as whether the injections can cause meningiomas, what manufacturers knew about the alleged risk, and whether their warnings were sufficient. Those questions explain why related cases were brought together for coordinated proceedings.
What Are Patients Alleging?
The claims concern intracranial meningiomas allegedly associated with Depo-Provera and related injectable products. Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC are identified as defendants in the court’s settlement-related case management order.
Patients’ allegations focus on the relationship between exposure, tumor development and warnings. Establishing an individual claim requires more than pointing to a study or an advertisement: the person’s product history and medical evidence matter. The settlement expressly involves no admission of fault or liability by the defendants.
What Does the Medical Research Show?
A French study published in The BMJ in March 2024 compared 18,061 women who underwent surgery for intracranial meningioma with 90,305 controls. Injectable medroxyprogesterone acetate was associated with higher odds of meningioma requiring surgery, with an odds ratio of 5.55. The increased risk was driven by prolonged use of at least one year.
That figure needs context. The injectable-drug finding involved nine exposed cases and 11 exposed controls, with a wide confidence interval. It does not mean that 55% of users develop tumors, or that an individual patient’s tumor was necessarily caused by the medication. The study was observational and examined an association rather than proving causation in each lawsuit.
Meningiomas arise in the membranes surrounding the brain and spinal cord. Many are noncancerous, but a tumor’s location and pressure on surrounding structures can still make it medically serious. Describing every claim as “brain cancer” would therefore be misleading.
Does the Current Label Warn About Meningioma?
Yes. FDA labeling revised in December 2025 includes a meningioma warning. It describes reports following repeated medroxyprogesterone acetate administration, primarily with long-term use. The Depo-Provera CI label directs clinicians to monitor patients for signs and symptoms and to discontinue the drug if a meningioma is diagnosed.
The warning appears separately from the boxed warning about bone mineral density. An article stating that the current U.S. label contains no meningioma warning would be outdated. The newer language does not, by itself, resolve disputes over earlier warnings or establish liability for a particular patient’s injury.
Has There Been a Depo-Provera Settlement?
Yes. Case Management Order No. 12 records that counsel announced a settlement on June 15, 2026, covering a majority of claims in the federal MDL and New York state court. A master settlement agreement followed in July. The court described it as a private agreement with confidential terms, and eligibility is governed by that agreement.
The settlement also changed the trial schedule: the court canceled the previously scheduled December trial involving the original pilot cases. This does not mean every lawsuit ended. The court established separate procedures for cases continuing outside the settlement program.
In August, the court appointed BrownGreer PLC as settlement administrator. Its responsibilities include reviewing submissions and supporting documents, determining eligibility, and coordinating the settlement process. Registering a claim is therefore different from receiving approval or payment. A reliable update should not promise a standard payout to every claimant or present speculative compensation ranges as established amounts.
What Deadline Should Claimants Check?
The August 10, 2026 case management order identifies November 30, 2026 as the registration deadline for the settlement program. Claimants should confirm the applicable requirements and any subsequent changes with their lawyer.
That date concerns settlement registration. It should not be treated as a universal deadline for filing every Depo-Provera lawsuit. Someone reviewing a possible claim should gather injection records, diagnosis reports and relevant treatment records, then obtain advice about the deadlines and procedures that apply to their circumstances.
Frequently Asked Questions
Q. Is this a class action with automatic compensation?
No. The court expressly states that the MDL is not a class action. Related individual cases are coordinated, but settlement participation depends on the agreement’s eligibility requirements. Having used Depo-Provera does not automatically establish entitlement to payment. Claimants should ask their lawyer to explain eligibility, required documentation and what accepting a settlement would release.
Q. Can claims involve generic injections or Depo-SubQ Provera 104?
The court’s ongoing-litigation order identifies Depo-Provera, Depo-SubQ Provera 104 and authorized generic versions among the products involved. That does not mean every injectable contraceptive or every generic manufacturer is covered. Records identifying the exact product, manufacturer, dose and injection dates help determine which claims and settlement provisions may apply.
Q. Should a current user change treatment because of the lawsuit?
Discuss the warning and your medical history with the prescribing clinician before your next injection. The lawsuit does not determine the best contraceptive option for every patient. If a meningioma has been diagnosed, the Depo-Provera CI label directs discontinuation; your clinician can manage that change and discuss alternative contraception.